Upon failure of first-line ADT, should second-line hormonal manipulation without survival benefit data still be used?

[1]  I. Tannock,et al.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  I. Tannock,et al.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  D. Dearnaley,et al.  A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. , 2015, European urology.

[4]  F. Saad,et al.  Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). , 2014, European urology.

[5]  F. Saad,et al.  753OFINAL OVERALL SURVIVAL (OS) ANALYSIS OF COU-AA-302, A RANDOMIZED PHASE 3 STUDY OF ABIRATERONE ACETATE (AA) IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS) WITHOUT PRIOR CHEMOTHERAPY. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  D. Dearnaley,et al.  764PDA RANDOMISED PHASE II TRIAL OF DEXAMETHASONE VERSUS PREDNISOLONE IN CASTRATION RESISTANT PROSTATE CANCER. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  K. Kihara,et al.  Prostate‐specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration‐resistant prostate cancer , 2012, BJU international.

[8]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.

[9]  C. Tangen,et al.  Antiandrogen withdrawal in castrate‐refractory prostate cancer , 2008, Cancer.

[10]  L. Ngo,et al.  Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore. , 2007, Annals of the Academy of Medicine, Singapore.

[11]  R. Jennrich,et al.  Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. , 2005, The Journal of urology.

[12]  K. Akakura,et al.  Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. , 2004, The Journal of urology.

[13]  W. Kassouf,et al.  Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. , 2003, The Journal of urology.

[14]  W. Stadler,et al.  Nilutamide: possible utility as a second-line hormonal agent. , 2001, Urology.

[15]  C. Moinpour,et al.  Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). , 2001, Urology.

[16]  L. Schwartz,et al.  Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  N. Bissada,et al.  Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. , 1995, The Journal of urology.

[18]  W. Lowrance,et al.  Castration-resistant prostate cancer: AUA guideline amendment. , 2015, The Journal of urology.

[19]  Thomas Wiegel,et al.  Guidelines on Prostate Cancer , 2013 .

[20]  G. Bubley,et al.  High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. , 1998, The Journal of urology.